Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6 Pt 1
|
| pubmed:dateCreated |
1994-3-23
|
| pubmed:abstractText |
Pulmonary hypertension leading to donor right ventricular dysfunction remains a major risk factor associated with poor outcome after heart transplantation. This study evaluated a pretransplantation protocol to assess pulmonary vascular resistance index and its response to pharmacologic modulation. Cardiac catheterization was performed in 25 patients (mean age, 8.6 years [range, 1 to 17 years]; mean weight, 27.3 kg [range, 8.1 to 54 kg]) with end-stage heart failure. Mean pulmonary artery and capillary wedge pressures and cardiac index were measured in the baseline state and during administration of 100% oxygen, dobutamine at 10 micrograms/kg/min, and nitroprusside at 1 to 4 micrograms/kg/min. Transpulmonary pressure gradient and pulmonary vascular resistance index were calculated. In 22 survivors, hemodynamics were reassessed 1 and 4 weeks after transplantation. The mean cardiac index significantly increased (2.2 to 3.2 L/min/m2); transpulmonary pressure gradient (12.7 to 9.6 mm Hg) and pulmonary vascular resistance index (6.2 to 3.0 units/m2) decreased during the drug study. In 12 patients with a baseline pulmonary vascular resistance index of more than 6 units/m2, 10 survived heart transplantation. This study shows that pharmacologic reduction of the pulmonary vascular resistance index in the pretransplantation protocol predicts reduced pulmonary vascular resistance index and a favorable outcome after heart transplantation.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1053-2498
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
12
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
965-72; discussion 972-3
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:8312321-Adolescent,
pubmed-meshheading:8312321-Amrinone,
pubmed-meshheading:8312321-Blood Pressure,
pubmed-meshheading:8312321-Cardiac Output,
pubmed-meshheading:8312321-Child,
pubmed-meshheading:8312321-Child, Preschool,
pubmed-meshheading:8312321-Dobutamine,
pubmed-meshheading:8312321-Drug Therapy, Combination,
pubmed-meshheading:8312321-Heart Transplantation,
pubmed-meshheading:8312321-Humans,
pubmed-meshheading:8312321-Hypertension, Pulmonary,
pubmed-meshheading:8312321-Infant,
pubmed-meshheading:8312321-Lung,
pubmed-meshheading:8312321-Nitroprusside,
pubmed-meshheading:8312321-Pulmonary Artery,
pubmed-meshheading:8312321-Pulmonary Circulation,
pubmed-meshheading:8312321-Pulmonary Wedge Pressure,
pubmed-meshheading:8312321-Vascular Resistance
|
| pubmed:articleTitle |
Pharmacologic reduction of pretransplantation pulmonary vascular resistance predicts outcome after pediatric heart transplantation.
|
| pubmed:affiliation |
Division of Cardiology, Children's Memorial Hospital, Chicago, IL 60614.
|
| pubmed:publicationType |
Journal Article
|